The global radiopharmaceuticals market is gaining momentum as nuclear medicine becomes increasingly important in disease diagnosis, molecular imaging, and targeted treatment. Radiopharmaceuticals contain radioactive isotopes that help healthcare professionals identify diseases, assess biological processes, and deliver radiation to specific tissues. Their applications are expanding across oncology, cardiology, and neurology, supported by advances in PET and SPECT imaging and the growing adoption of targeted radionuclide therapies. Increasing investments in isotope production, radiopharmacy infrastructure, and clinical research are further shaping the industry's growth.

Download a free sample copy of the Radiopharmaceuticals market report to understand detailed coverage and inclusions in the final report

Track Market Growth and Metrics

According to Grand View Research, the global radiopharmaceuticals market was valued at USD 10.3 billion in 2025 and is estimated to reach USD 11.0 billion in 2026. The market is projected to reach USD 33.4 billion by 2040, registering a compound annual growth rate (CAGR) of 8.2% from 2026 to 2040. The report's current forecast extends to 2040, rather than 2033.

Key market metrics include:

• 2025 market size: USD 10.3 billion
• 2026 estimated market size: USD 11.0 billion
• 2040 projected market size: USD 33.4 billion
• Market CAGR:2% from 2026 to 2040
• Largest region: North America, with 51.2% revenue share in 2025
• Leading product category: Diagnostic radiopharmaceuticals, with 75.5% share in 2025
• Largest end-use segment: Hospitals, with 49.8% share in 2025

The growing use of molecular imaging and targeted cancer treatments is expected to support demand for radiopharmaceutical products. However, reliable isotope availability and specialized distribution infrastructure will remain essential to market expansion.

Pinpoint Key Market Drivers

The increasing adoption of PET-based molecular imaging is a major growth driver. PET radiopharmaceuticals provide information about metabolic activity and molecular targets, helping physicians detect cancer, assess disease progression, and monitor treatment response. Fluorine-18 FDG remains widely used in oncology, while targeted tracers such as prostate-specific membrane antigen (PSMA) agents are expanding imaging applications in prostate cancer.

The rising prevalence of cancer is also increasing demand for diagnostic and therapeutic radiopharmaceuticals. These products support tumor detection, staging, treatment planning, and targeted radiation delivery. Lutetium-177-based therapies are gaining clinical importance because they can deliver radiation to cancer cells expressing specific molecular targets.

Another important driver is the expansion of nuclear medicine infrastructure. Investments in PET and SPECT scanners, cyclotrons, radiopharmacies, and specialized treatment centers are improving access to nuclear medicine procedures. Nevertheless, limited isotope production capacity, high infrastructure costs, regulatory requirements, and time-sensitive transportation can restrict supply and adoption.

Go Deeper! Ask Prism AI

about the Global Radiopharmaceuticals Market. Get instant answers to questions related to market sizing, growth drivers & their impact, and more.

Analyze Segment Metrics

By product, diagnostic radiopharmaceuticals held the largest share, accounting for 75.5% of market revenue in 2025. Their widespread use in PET and SPECT procedures supports this position. Technetium-99m-based products are particularly important in routine nuclear medicine examinations, including cardiac, bone, renal, thyroid, and lung imaging.

Within diagnostic imaging modalities, SPECT radiopharmaceuticals accounted for 74.5% of revenue in 2025. PET radiopharmaceuticals are expected to register the fastest growth within this category, with a projected CAGR of 9.0%. Increasing oncology imaging volumes and the development of targeted molecular tracers are supporting PET adoption.

By application, oncology imaging represented the largest share, accounting for 38.1% of revenue in 2025. Radiopharmaceuticals are widely used for cancer detection, staging, and treatment monitoring. Neurology imaging is expected to grow at the fastest CAGR of 9.2%, supported by increasing PET applications in Alzheimer's disease assessment, amyloid imaging, and neurological biomarker research.

By end use, hospitals held the largest revenue share of 49.8% in 2025. Their nuclear medicine departments, trained specialists, and established imaging infrastructure support high product utilization. Specialty clinics and catheterization laboratories are expected to grow fastest, with a projected CAGR of 10.7%, as nuclear cardiology and specialized oncology services expand.

Identify Major Industry Players

The competitive landscape includes pharmaceutical companies, nuclear medicine suppliers, isotope manufacturers, and developers of targeted radiotherapies. Major industry participants include:

• Lantheus
• Curium
• GE HealthCare
• Jubilant Radiopharma
• Blue Earth Diagnostics (Bracco)
• NCM USA
• Novartis
• Bayer AG
• Telix Pharmaceuticals
• Eckert & Ziegler
• Sirtex Medical
• Boston Scientific
• AstraZeneca / Fusion Pharmaceuticals
• Actinium Pharmaceuticals

Companies are focusing on product development, isotope sourcing, manufacturing expansion, strategic collaborations, and geographic distribution. Competition is increasingly shaped by access to specialized radionuclides, clinical pipelines, production capabilities, and relationships with hospitals and radiopharmacies.

Looking for more specific insights? Customize this report to suite your business needs

Spot Emerging 2026 Trends

Several developments are influencing the radiopharmaceuticals market in 2026. Theranostics is becoming increasingly important because it connects molecular imaging with targeted radionuclide treatment. Diagnostic tracers help identify patients whose tumors express specific molecular targets, while corresponding therapeutic agents deliver radiation to those cells. This approach is supporting more personalized cancer care.

The development of targeted alpha therapies is another significant trend. Actinium-225 is attracting attention for its potential in targeted cancer treatment, although production capacity and supply availability remain challenges. In May 2026, TerraPower Isotopes began construction of a large-scale cGMP Ac-225 manufacturing facility in Philadelphia, highlighting growing investment in therapeutic isotope production.

Advances in PET tracer development are also expanding clinical applications. In September 2026, Telix Pharmaceuticals received U.S. FDA approval for Pixclara, a fluorine-18-based PET imaging product for brain tumor imaging in adults and pediatric patients with suspected or known glioma.

U.S. Healthcare Facility Mapping & Intelligence Platform - https://www.grandviewresearch.com/horizon/hospital-database

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.